StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.47−0.39 (-1.35%)

Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%

Pfizer revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Pfizer's revenue for the twelve months ending Jun 28, 2026 was $63.70B, down 0.2% year over year. For fiscal 2025 it was $62.58B, down 1.6% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $101.18B in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$62.58B-1.6%
FY2024Dec 31, 2024$63.63B+6.8%
FY2023Dec 31, 2023$59.55B-41.1%
FY2022Dec 31, 2022$101.18B+24.5%
FY2021Dec 31, 2021$81.29B+95.2%
FY2020Dec 31, 2020$41.65B+1.8%
FY2019Dec 31, 2019$40.91B+0.2%
FY2018Dec 31, 2018$40.83B-22.3%
FY2017Dec 31, 2017$52.55B-0.5%
FY2016Dec 31, 2016$52.82B+8.1%
FY2015Dec 31, 2015$48.85B-1.5%
FY2014Dec 31, 2014$49.61B-3.8%
FY2013Dec 31, 2013$51.58B-5.6%
FY2012Dec 31, 2012$54.66B-10.4%
FY2011Dec 31, 2011$61.04B-6.3%
FY2010Dec 31, 2010$65.17B+32.3%
FY2009Dec 31, 2009$49.27B+2.0%
FY2008Dec 31, 2008$48.30B-0.3%
FY2007Dec 31, 2007$48.42B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026$15.03B+2.6%
Q1 FY2026Mar 29, 2026$14.45B+5.4%
Q4 FY2025Dec 31, 2025$17.56B-1.2%
Q3 FY2025Sep 28, 2025$16.65B-5.9%
Q2 FY2025Jun 29, 2025$14.65B+10.3%
Q1 FY2025Mar 30, 2025$13.72B-7.8%
Q4 FY2024Dec 31, 2024$17.76B+21.9%
Q3 FY2024Sep 29, 2024$17.70B+31.2%
Q2 FY2024Jun 30, 2024$13.28B+2.1%
Q1 FY2024Mar 31, 2024$14.88B-19.5%
Q4 FY2023Dec 31, 2023$14.57B-42.0%
Q3 FY2023Oct 1, 2023$13.49B-40.4%
Q2 FY2023Jul 2, 2023$13.01B-53.1%
Q1 FY2023Apr 2, 2023$18.49B-28.0%
Q4 FY2022Dec 31, 2022$25.14B+5.4%
Q3 FY2022Oct 2, 2022$22.64B-5.8%
Q2 FY2022Jul 3, 2022$27.74B+46.8%
Q1 FY2022Apr 3, 2022$25.66B+76.8%
Q4 FY2021Dec 31, 2021$23.84B+108.6%
Q3 FY2021Oct 3, 2021$24.04B+133.9%
Q2 FY2021Jul 4, 2021$18.90B+91.6%
Q1 FY2021Apr 4, 2021$14.52B+44.0%
Q4 FY2020Dec 31, 2020$11.43B+520.0%
Q3 FY2020Sep 27, 2020$10.28B-19.0%
Q2 FY2020Jun 28, 2020$9.86B-25.6%
Q1 FY2020Mar 29, 2020$10.08B-23.1%
Q4 FY2019Dec 31, 2019$1.84B+59.6%
Q3 FY2019Sep 29, 2019$12.68B-4.6%
Q2 FY2019Jun 30, 2019$13.26B-1.5%
Q1 FY2019Mar 31, 2019$13.12B+1.6%
Q4 FY2018Dec 31, 2018$1.16B-91.6%
Q3 FY2018Sep 30, 2018$13.30B+1.0%
Q2 FY2018Jul 1, 2018$13.47B+4.4%
Q1 FY2018Apr 1, 2018$12.91B+1.0%
Q4 FY2017Dec 31, 2017$13.70B+0.6%
Q3 FY2017Oct 1, 2017$13.17B+0.9%
Q2 FY2017Jul 2, 2017$12.90B–
Q1 FY2017Apr 2, 2017$12.78B–
Q4 FY2016Dec 31, 2016$13.63B–
Q3 FY2016Oct 2, 2016$13.05B–

More Pfizer figures

See a number that looks wrong?